A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits.
Cyclosporin-A (CyA) administered to rabbits intramuscularly in a dose of 25 mg/kg/day for 14 days following interlamellar corneal grafting had a significant effect in preventing rejection of the corneal graft (p less than 0.05), and the benefit was maintained. Rejection was attended by an initial mild inflammatory reaction and followed by a protracted intense response involving a variety of cell types, with subsequent loss of epithelium. endothelium and keratocytes, and the development of areas of stromal necrosis. CyA suppressed this rejection response.
D000818:Animals; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D016039:Corneal Transplantation; D003524:Cyclosporins / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000187:drug effects*; D011817:Rabbits
D003524:Cyclosporins